Predictive Oncology (NASDAQ: POAI) Featured in Broadcast on Big Data, AI’s Potential to Fight Cancer
October 31 2019 - 8:30AM
via NetworkNewsAudio –
Predictive Oncology
(NASDAQ: POAI) announces the availability of a broadcast
titled, “Delivering Precision Medicine’s True Potential: Big Data,
Artificial Intelligence Identify New Cancer Therapeutics.”
To hear the NetworkNewsWire Audio version, visit:
http://nnw.fm/8zJx5
To read the full editorial, visit: http://nnw.fm/j6Orz
For some time, clinicians have been utilizing key genomic data
to understand a patient’s individual tumor type in attempts to
effectively prescribe therapies that will work. However, the
scientific community has come to realize, due to low success rates
in these applications, that genomic data itself — utilizing a
just-genomics approach — doesn’t fully address the complexities of
cancer and is merely scratching the surface of personalized
medicine’s true potential. The precision-medicine space has a real
unmet need, with a surging demand for a multi-omic approach rather
than just genomics to better understand and treat the complexities
of cancer.
Major players in the space are looking to get their hands on
comprehensive, multi-omic data sets that can help them not only
understand the type of cancer a patient may have but also strongly
predict which therapies will be most effective in fighting each
specific cancer. Unfortunately, such data is fragmented and scarce,
and the initiation of such data collecting is costly and time
consuming. Predictive Oncology (NASDAQ: POAI) has already
assembled one of the largest databases of drug-response and outcome
data in the world.
About Predictive Oncology Inc.
Predictive Oncology is an AI-driven company focused on applying
artificial intelligence to personalized medicine and drug
discovery. The company applies smart tumor profiling and its AI
platform to extensive genomic and biomarker patient data sets to
predict clinical outcomes and, most importantly, improve patient
outcomes for cancer patients of today and tomorrow. Predictive
Oncology currently has approximately 150,000 clinically validated
cases on its molecular information platform, with more than 38,000
specific to ovarian cancer. The company’s data is highly
differentiated, having both drug-response data and access to
historical outcome data from patients. Predictive Oncology intends
to generate additional sequence data from these tumor samples to
deliver on the clear unmet market need across the pharmaceutical
industry for a multi-omic approach to new drug development. For
more information, visit the company’s website
at www.Predictive-Oncology.com.
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution,
allows you to sit back and listen to market updates, CEO interviews
and a Company AudioPressRelease (APR). These audio clips provide
snapshots of position, opportunity and
momentum. NetworkNewsAudio (NNA) can assist your company
by cutting through the overload of information in today's market,
NNA brings its clients unparalleled visibility, recognition and
brand awareness. NetworkNewsWire (NNW) is where news,
content and information converge. NetworkNewsWire
(NNW) is a comprehensive provider of news aggregation and
syndication, enhanced press release services and a full array of
social communication solutions. As a multifaceted financial news
and distribution company with an extensive team of journalists and
writers, NNW has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of more than 5,000 key
syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024